-
A New Era for Diabetes Care: FDA Approves Awiqli for Children and Adolescents
NYSE: $NVO A Breakthrough in Insulin Therapy Managing type 1 and type 2 diabetes has long required the demanding routine of daily insulin injections. However, a significant advancement has arrived. The FDA has officially approved Awiqli (insulin icodec), marking it as the first and only once-weekly basal insulin for children and adolescents aged 10 years…
-
CagriSema: The Breakthrough Combo Targeting ‘Food Noise’ and Metabolic Health
A New Frontier in Weight Management Recent clinical updates regarding CagriSema, an investigational drug developed by Novo Nordisk, are generating significant buzz in the medical community. This once-weekly injectable treatment combines semaglutide with cagrilintide, offering a dual-action approach to treating obesity and type 2 diabetes. Silencing ‘Food Noise’ One of the most compelling aspects of…
-
Boehringer Ingelheim’s Survodutide Achieves up to 13.1% Weight Loss in New Phase III Trial, Alongside Significant Improvements in Glycemic Control in People with Obesity and Type 2 Diabetes
Ingelheim, Germany, October 1, 2026 — Boehringer Ingelheim today announced positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with… Source: Read More
-
FDA Approves Garzuly: A New Biosimilar Option for Insulin Aspart
A New Milestone in Diabetes Care The FDA has officially granted approval for Garzuly (insulin aspart), a significant development for patients managing diabetes. As a biosimilar to NovoLog, Garzuly offers an alternative treatment option for individuals requiring insulin aspart to improve glycemic control. What You Need to Know About Garzuly Biosimilars are designed to be…
-
A Breakthrough in Diabetes Care: Afrezza Approved for Children and Adolescents
A New Chapter for Pediatric Diabetes Management For many families managing diabetes, the daily routine of injections can be a significant source of stress and discomfort. MannKind Corporation has recently reached a major milestone in diabetes treatment: the FDA has officially approved Afrezza (insulin human) inhalation powder for use in children and adolescents with diabetes.…
-
Biomea Fusion | Presenting New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
NASDAQ: BMEA BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes STOCK & PRESS RELEASE INFO